Synagistics Limited — Share Issue/Capital Change 2018

Feb 1, 2018

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [66 x 45] intentionally omitted <==

==> picture [34 x 40] intentionally omitted <==

OP FINANCIAL INVESTMENTS LIMITED 東英金融投資有限公司[*]

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1140)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“ Stock Exchange ”).

The board (the “ Board ”) of directors (the “ Directors ”) of OP Financial Investments Limited (the “ Company ”) hereby announces that on 1 February 2018 (“ Date of Grant ”) the Company granted 22,000,000 share options (“ Options ”) to certain eligible grantees (“ Grantees ”) of the Company and its subsidiaries (the “ Group ”) under the share option scheme of the Company adopted on 17 May 2016, subject to the acceptance of the offer by the Grantees. The Options shall entitle the Grantees to subscribe for a total of 22,000,000 new ordinary shares of HK$0.1 each (“ Shares ”) in the share capital of the Company. Details of the Options granted are as follows:

Date of Grant:

1 February 2018

Exercise price of HK$2.60 per Share Options granted:

(which is higher than the highest of (i) the closing price of HK$2.57 as stated in the Stock Exchange’s daily quotations sheet on the Date of Grant; and (ii) the average closing price of HK$2.55 per Share as stated in the Stock Exchange’s daily quotations sheets for the five business days immediately preceding the Date of Grant).

Number of Options granted: 22,000,000 Options (each Option shall entitle the Grantee thereof to subscribe for one Share)

Closing price of the Shares HK$2.57 per Share on the Date of Grant:

• For identification purposes only

– 1 –

Validity period of the Options:

Five years from the Date of Grant, i.e. from 1 February 2018 to 31 January 2023 (both days inclusive), and the Options shall lapse at the expiry of the validity period

Vesting schedule of the Options:

The Options shall be exercisable in four tranches in accordance with the following dates:

• (i) 25% of the Options shall be exercisable at any time on or after the first anniversary of the Date of Grant, i.e. 1 February 2019 and expiring on 31 January 2023;

• (ii) 25% of the Options shall be exercisable at any time on or after the second anniversary of the Date of Grant, i.e. 1 February 2020 and expiring on 31 January 2023;

• (iii) 25% of the Options shall be exercisable at any time on or after the third anniversary of the Date of Grant, i.e. 1 February 2021 and expiring on 31 January 2023; and

• (iv) 25% of the Options shall be exercisable at any time on or after the fourth anniversary of the Date of Grant, i.e. 1 February 2022 and expiring on 31 January 2023.

10,000,000 out of 22,000,000 Options were granted to one of the Directors, with details as follows:

Name of the Grantee Position Number of Options granted Dr. Wu Zhong Non Executive Director 10,000,000

Save as disclosed above, none of the other Grantees were a Director, chief executive, substantial shareholder of the Company, nor an associate of any of them (as defined in the Listing Rules).

In accordance with Rule 17.04(1) of the Listing Rules, the grant of Options to the above director has been approved by the independent non-executive Directors of the Company on 1 February 2018.

By order of the Board OP Financial Investments Limited Zhang Gaobo Executive Director & CEO

Hong Kong, 1 February 2018

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Zhang Zhi Ping, Mr. Zhang Gaobo, Dr. Liu Zhiwei and Mr. Zhang Weidong; one nonexecutive Director, namely Dr. Wu Zhong and three independent non-executive Directors, namely, Mr. Kwong Che Keung, Gordon, Professor He Jia and Mr. Wang Xiaojun.

– 2 –